Loading...
XETRNXU
Market cap1.25bUSD
Dec 23, Last price  
69.50EUR
1D
-0.57%
1Q
30.89%
Jan 2017
287.62%
Name

Nexus AG

Chart & Performance

D1W1MN
XETR:NXU chart
P/E
49.89
P/S
4.97
EPS
1.39
Div Yield, %
0.30%
Shrs. gr., 5y
1.86%
Rev. gr., 5y
12.09%
Revenues
241m
+15.46%
16,395,00020,983,00026,121,00029,712,00034,824,00040,363,00044,823,00053,534,00062,340,00073,263,00080,147,00097,269,000107,051,000119,083,000136,469,000147,648,000162,944,000188,178,000209,128,000241,459,000
Net income
24m
+24.21%
-470,000262,000525,0001,163,0001,533,0002,103,0003,538,0004,695,0006,128,0007,601,0008,279,0007,583,0008,146,0009,832,00010,921,00010,841,00014,916,00017,153,00019,347,00024,031,000
CFO
30m
-10.24%
7,849,0005,620,0001,825,0002,528,0004,258,0007,313,00013,929,00010,995,0008,276,00010,544,00011,594,00018,145,00016,542,00021,677,00020,241,00024,618,00030,947,00031,386,00033,875,00030,407,000
Dividend
May 16, 20240.22 EUR/sh
Earnings
Mar 03, 2025

Profile

Nexus AG develops and sells software and hardware solutions, and provides IT services, primarily for customers in the health care system worldwide. It operates in two divisions, Healthcare Software and Healthcare Services. The company offers information systems, such as NEXUS/HIS and KIS for somatic hospitals; NEXUS/PSYCHIATRY for psychiatric institutions; NEXUS/REHAB for rehabilitation facilities; ITR, a software for rehabilitation, clinics, and hotels with medical care; NEXUS/ARCHIVE and PEGASOS, an archiving and process management system; NEXUS/QM for quality management; NEXUS/INTEGRATION SERVER, an interface management; NEXUS/CLOUD IT, outsourcing solution; NEXUS/EPS, a software solution to supplement SAP personnel management, as well as process and HR consulting in the SAP environment; ifa systems, an ophthalmology software solution; Sophrona solutions, ophthalmology patients and referral program; and NEXUS/DIS, interdisciplinary diagnostic information system. Its information systems also comprise NEXUS/SWISSLAB, a laboratory information system; NEXUS/LAURIS for order communication in diagnostics; NEXUS/PATHOLOGY and NEXUS/CYTOLOGY for pathology and cytology institutes; dc-Pathos and dc-LabMan for pathology and cytology devices; NEXUS/RADIOLOGY, an information and image system for radiology wards and offices; NEXUs/CHILI, for PACS and teleradiology solutions; NEXUS/ASTRAIA for obstetrics and gynecology; NEXUS/SPECIAL DIAGNOSTICS and Clinic WinData for medical specialist diagnostics and device integration; NEXUS/HOME for senior citizen and nursing homes; NEXUS/OUTPATIENT CARE and Asebis, a homecare solution; NEXUS/PAT, an administration system for hospitals; and osoTEC for billing personal and other services. In addition, the company offers SINAPSI, highsystemNET, CREATIV OM, SEXTANT, Emed, NEXUS/EPD, NEXUS/AEMP, NEXUS/SPM, EuroSDS, RVS Software, NEXUS/VITA and TESIS VITA, and NEXUS/ESKULAP. NEXUS AG is headquartered in Donaueschingen, Germany.
URL
https://www.nexus-ag.de/
IPO date
Jul 24, 2000
Employees
1,700
Domiciled in
DE
Incorporated in
DE

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
241,459
15.46%
209,128
11.13%
188,178
15.49%
Cost of revenue
236,916
86,752
37,679
Unusual Expense (Income)
NOPBT
4,543
122,376
150,499
NOPBT Margin
1.88%
58.52%
79.98%
Operating Taxes
9,202
7,491
5,596
Tax Rate
202.55%
6.12%
3.72%
NOPAT
(4,659)
114,885
144,903
Net income
24,031
24.21%
19,347
12.79%
17,153
15.00%
Dividends
(3,620)
(3,153)
(2,993)
Dividend yield
Proceeds from repurchase of equity
(1,386)
71,120
48
BB yield
Debt
Debt current
4,807
4,358
4,559
Long-term debt
35,683
32,984
28,703
Deferred revenue
Other long-term liabilities
39,492
16,601
22,506
Net debt
(61,146)
17,274
7,034
Cash flow
Cash from operating activities
30,407
33,875
31,386
CAPEX
(9,457)
(5,575)
(5,569)
Cash from investing activities
(17,022)
(98,552)
(21,249)
Cash from financing activities
(16,722)
57,969
(11,084)
FCF
(10,932)
111,374
139,418
Balance
Cash
99,004
110,952
26,302
Long term investments
2,632
(90,884)
(74)
Excess cash
89,563
9,612
16,819
Stockholders' equity
156,074
133,254
115,289
Invested Capital
228,756
251,703
152,984
ROIC
56.78%
99.88%
ROCE
1.38%
45.33%
83.53%
EV
Common stock shares outstanding
17,249
16,006
15,749
Price
Market cap
EV
EBITDA
23,059
138,880
167,155
EV/EBITDA
Interest
1,919
1,037
1,052
Interest/NOPBT
42.24%
0.85%
0.70%